Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Drug

Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma

Fineline Cube Aug 26, 2024

Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...

Company Drug

Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach

Fineline Cube Aug 26, 2024

Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...

Policy / Regulatory

China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments

Fineline Cube Aug 26, 2024

The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State...

Company Drug

Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments

Fineline Cube Aug 23, 2024

Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors

Fineline Cube Aug 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...

Company Drug

Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE

Fineline Cube Aug 23, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...

Company Deals

ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal

Fineline Cube Aug 23, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...

Company Drug

Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease

Fineline Cube Aug 23, 2024

Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301...

Company Drug

Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy

Fineline Cube Aug 23, 2024

Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...

Company

Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers

Fineline Cube Aug 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis

Fineline Cube Aug 23, 2024

Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...

Company Medical Device

Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA

Fineline Cube Aug 23, 2024

Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...

Company Deals

Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights

Fineline Cube Aug 23, 2024

Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals

Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases

Fineline Cube Aug 23, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...

Company Drug

UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection

Fineline Cube Aug 23, 2024

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...

Company

Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability

Fineline Cube Aug 23, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...

Company

3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength

Fineline Cube Aug 23, 2024

3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...

Company

Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy

Fineline Cube Aug 23, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...

Company Drug

Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors

Fineline Cube Aug 23, 2024

Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer

Fineline Cube Aug 23, 2024

Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...

Posts pagination

1 … 266 267 268 … 623

Recent updates

  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
  • Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist
  • GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Company Drug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.